<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616131</url>
  </required_header>
  <id_info>
    <org_study_id>21-012</org_study_id>
    <nct_id>NCT04616131</nct_id>
  </id_info>
  <brief_title>Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer</brief_title>
  <official_title>Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central DuPage Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elsa U. Pardee Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central DuPage Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients who have been diagnosed with pancreatic cancer that has not spread outside of&#xD;
      the pancreas and nearby lymph nodes. The purpose of this research study is to understand if&#xD;
      we are able to detect pancreatic cancer DNA in the blood stream before, during, and after&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer DNA in the blood stream is called circulating tumor DNA or ctDNA. The presence or&#xD;
      absence of pancreatic cancer ctDNA in the blood stream may help clinicians to better&#xD;
      understand pancreatic cancer behavior in response to specific treatments, like chemotherapy&#xD;
      and surgery. Understanding how treatment alters the ctDNA can help future patients diagnosed&#xD;
      with pancreatic cancer. The presence or absence of ctDNA or the clearance of ctDNA after&#xD;
      treatment may help to guide further treatment decisions for cancer patients after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected.</measure>
    <time_frame>3 months</time_frame>
    <description>Utilizing Tempus, a commercial laboratory ctDNA genetic profile panel investigators will analyze the number of patients who had detectable ctDNA in their blood prior to neoadjuvant chemotherapy who then had no detectable ctDNA after their chemotherapy treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigators will look for statistically significant correlations of ctDNA blood levels with clinical treatment responses of tumor grades, CA 19-9 units/milliliter blood level, and radiologic response by RECIST categories of complete response.</measure>
    <time_frame>12 months</time_frame>
    <description>Association of ctDNA clearance with the following: pathologic treatment response per CAP tumor regression grade 0,1,2, and 3, blood level measurement of protein CA 19-9 units/milliliter, and radiologic response by tumor measurements in mm and using RECIST tumor measurement categories of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) for all patients, and margin assessment (R0/R1 resection) in resected patients.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreas Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female individuals age 18 and over planning to receive chemotherapy for pancreatic&#xD;
        cancer that has not spread outside of the pancreas and nearby lymph nodes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy or cytology proven adenocarcinoma of the pancreas&#xD;
&#xD;
          -  No clinical evidence of metastatic disease on imaging&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Receiving chemotherapy for non-metastatic pancreatic cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akhil Chawla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Medicine Central DuPage Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akhil Chawla, MD</last_name>
    <phone>630-352-5353</phone>
    <email>Akhil.Chawla@nm.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donald Smith, MS</last_name>
    <phone>630-352-5360</phone>
    <email>Donald.Smith3@nm.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Kishwaukee</name>
      <address>
        <city>DeKalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Smith</last_name>
      <phone>630-352-5360</phone>
      <email>Donald.Smith3@nm.org</email>
    </contact>
    <investigator>
      <last_name>Robert Bayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Faisal Saghir, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Delnor</name>
      <address>
        <city>Geneva</city>
        <state>Illinois</state>
        <zip>60135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Smith</last_name>
      <phone>630-352-5360</phone>
      <email>donald.smith3@nm.org</email>
    </contact>
    <investigator>
      <last_name>Christopher George, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Habib Shaikh, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arlene D'Souza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Warrenville</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akhil Chawla, MD</last_name>
      <phone>630-352-5353</phone>
      <email>Akhil.Chawla@nm.org</email>
    </contact>
    <investigator>
      <last_name>Ahamed Zarzour, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Dawravoo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Abad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

